Úsek pro vědu a výzkum

doc. Mgr. Kateřina Machová Poláková, Ph.D.

vedoucí oddělení molekulární genetiky

Tel: +420 221 977 181, +420 221 977 272
Email: Katerina.Machova@uhkt.cz

Impaktované publikace

[21]

Mobius, S.; Schenk, T.; Himsel, D.; Maier, J.; Franke, G.-N.; Saussele, S.; Pott, C.; Andrikovics, H.; Meggyesi, N.; Machova-Polakova, K.; Zizkova, H.; et al.

Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)

[rok vydání 2019, impact factor 3.656 ]

[22]

Pavlik, T.; Janousova, E.; Mayer, J.; Indrak, K.; Jarosova, M.; Klamova, H.; Zackova, D.; Voglova, J.; Faber, E.; Karas, M.; Machova Polakova, K.; Racil, Z.; Demeckova, E.; Demitrovicova, L.; Tothova, E.; Chudej, J.; Markuljak, I.; Cmunt, E.; Kozak, T.; Muzik, J.; Dusek, L.

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

[rok vydání 2013, impact factor 3.477 ]

[23]

Soverini, S.; De Benedittis, C.; Castagnetti F.; Gugliotta, G.; Mancini, M.; Bavaro, L.; Machova Polakova, K.; Linhartova, J.; Iurlo, A.; Russo, D.; Pane, F.; Saglio, G.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

[rok vydání 2016, impact factor 3.288 ]

[24]

Preuner, S.; Barna, A.; Frommlet, F.; Czurda, S.; Konstantin, B.; Alikian, M.; Machova Polakova, K.; Sacha, T.; Richter, J.; Lion, T.; Gabriel, C.

Quantitative analysis of mutant subclones in chronic myeloid leukemia: comparison of different methodological approaches

[rok vydání 2016, impact factor 3.226 ]

[25]

Machová Poláková, K.; Polívková, V.; Rulcová, J.; Klamová, H.; Jurček, T.; Dvořáková, D.; Žáčková, D.; Pospíšil, Z.; Mayer, J.; Moravcová, J.

Constant BCR-ABL transcript level less than or equal 0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

[rok vydání 2009, impact factor 3.198]

[26]

Machova Polakova, K.; Kulvait, V.; Benesova, A.; Linhartova, J.; Klamova, H.; Jaruskova, M.; de Benedittis, C.; Haferlach, T.; Baccarani, M.; Martinelli, G.; Stopka, T.; Ernst, T.; Hochhaus, A.; Kohlmann, A.; Soverini, S.

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

[rok vydání 2014, impact factor 3.141 ]

[27]

Racil, Z.; Razga, F.; Klamova, H.; Voglova, J.; Belohlavkova, P.; Malaskova, L.; Potesil, D.; Muzik, J.; Zackova, D.; Machova Polakova, K.; Zdrahal, Z.; Malakova, J.; Suttnar, J.; Dyr, J.; Mayer, J.

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

[rok vydání 2013, impact factor 3.084 ]

[28]

Racil, Z.; Razga, F.; Klamova, H.; Voglova, J.; Belohlavkova, P.; Malaskova, L.; Potesil, D.; Muzik, J.; Zackova, D.; Polakova, K.M.; Zdrahal, Z.; Malakova, J.; Suttnar, J.; Dyr, J.; Mayer, J.

Erratum: No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

[rok vydání 2015, impact factor 3.084 ]

[29]

Šmahelová, J.; Kaštánková, I.; Poláková, K.M.; Klamová, H.; Zemanová, K.; Tachezy, R.; Hamšíková, E.; Šmahel, M.

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

[rok vydání 2017, impact factor 2.976 ]

[30]

Polivkova, V.; Rohon, P.; Klamova, H.; Cerna, O.; Divoka, M.; Curik, N.; Zach, J.; Novak, M.; Marinov, I.; Soverini, S.; Faber, E.; Machova Polakova, K.

Interferon-alpha revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients

[rok vydání 2016, impact factor 2.806 ]

[31]

Koblihova, J.; Srutova, K.; Krutska, M.; Klamova, H.; Polakova, K.M.

AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome

[rok vydání 2018, impact factor 2.776 ]

[32]

Toman, O.; Kabickova, T.; Vit, O.; Fiser, R.; Machova Polakova, K.; Zach, J.; Linhartova, J.; Vyoral, D.; Petrak, J.

Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target

[rok vydání 2016, impact factor 2.662 ]

[33]

Zackova, D.; Klamova, H.; Muzik, J.; Cmunt, E.; Racil, Z.; Machova Polakova, K.; Dvorakova, D.; Jurcek, T.; Razga, F.; Cetkovsky, P.; Dusek, L.; Mayer, J.

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for chronic myeloid leukemia patients treated in three different hospitals compare well with results achievable in formal clinical trials

[rok vydání 2013, impact factor 2.605 ]

[34]

Racil, Z.; Razga, F.; Machova Polakova, K.; Buresova, K.; Polivkova, V.; Dvorakova, D.; Zackova, D.; Klamova, H.; Cetkovsky, P.; Mayer, J.

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia : the role of different cell types

[rok vydání 2011, impact factor 2.580]

[35]

Machova Polakova, K.; Lopotova, T.; Klamova, H.; Moravcova, J.

High-resolution melt curve analysis : initial screening for mutations in BCR-ABL kinase domain

[rok vydání 2008, impact factor 2.390]

[36]

Moravcova, J.; Rulcova, J.; Machova Polakova, K.; Klamova, H.

Control genes in international standardization of real-time RT-PCR for BCR-ABL

[rok vydání 2008, impact factor 2.358]

[37]

Klamová, H.; Marková, M.; Moravcová, J.; Šišková, M.; Cetkovský, P.; Machová Poláková, K.

Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery

[rok vydání 2009, impact factor 2.358]

[38]

Machova Polakova, K.; Koblihova, J.; Stopka, T.

Role of epigenetics in chronic myeloid leukemia

[rok vydání 2013, impact factor 2.286 ]

[39]

Machova Polakova, K.; Zmekova, V.; Rulcova, J.; Klamova, H.; Zemanova, Z.; Moravcova, J.

BCR-ABL mutations in chronic myeloid leukemia : not only detection

[rok vydání 2008, impact factor 1.939]

[40]

Klamova, H.; Faber, E.; Zackova, D.; Markova, M.; Voglova, J.; Cmunt, E.; Novakova, L.; Machova-Polakova, K.; Moravcova, J.; Dvorakova, D.; Michalova, K.; Brezinova, J.; Oltova, A.; Jarosova, M.; Cetkovsky, P.; Indrak, K.; Mayer, J.

Dasatinib in imatinib-resistant or -intolerant CML patients : data from the clinical practice of 6 hematological centers in the Czech Republic

[rok vydání 2010, impact factor 1.449]